Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801477219> ?p ?o ?g. }
- W2801477219 endingPage "403" @default.
- W2801477219 startingPage "395" @default.
- W2801477219 abstract "Although sorafenib (SFB) showed improved efficacy and much reduced the side effects in clinical liver cancer therapy, its therapeutic efficacy was still greatly limited due to short half-life in vivo as well as drug resistance. To solve these problems, we developed a novel SFB-loaded polymeric nanoparticle for targeted therapy of liver cancer. This polymeric nanoparticle, referred to NP-SFB-Ab, was fabricated from self-assembly of biodegradable block copolymers TPGS-b-poly(caprolactone) (TPGS-b-PCL) and Pluronic P123 and drug SFB, followed by conjugating the anti-GPC3 antibody. NP-SFB-Ab showed robust stability and achieve excellent SFB release in cell medium. The CLSM demonstrated that the Ab-conjugated NP exhibited much higher cellular uptake in HepG2 human liver cells than non-targeted NP. The MTT assay also confirmed that NP-SFB-Ab caused much greater cytotoxicity than non-targeted NP-SFB and free SFB. Finally, NP-SFB-Ab was proved to greatly inhibit the tumor growth of HepG2 xenograft-bearing nude mice without obvious side effects. Therefore, this NP-SFB-Ab provides a promising new approach for targeted therapy of hepatocellular carcinoma." @default.
- W2801477219 created "2018-05-17" @default.
- W2801477219 creator A5009789022 @default.
- W2801477219 creator A5011690431 @default.
- W2801477219 creator A5014059510 @default.
- W2801477219 creator A5020397284 @default.
- W2801477219 creator A5025180804 @default.
- W2801477219 creator A5040353743 @default.
- W2801477219 creator A5054192701 @default.
- W2801477219 creator A5058106018 @default.
- W2801477219 creator A5058492742 @default.
- W2801477219 creator A5068506600 @default.
- W2801477219 creator A5077056772 @default.
- W2801477219 creator A5079609030 @default.
- W2801477219 creator A5085792068 @default.
- W2801477219 date "2018-10-01" @default.
- W2801477219 modified "2023-10-16" @default.
- W2801477219 title "Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma" @default.
- W2801477219 cites W1963615455 @default.
- W2801477219 cites W1971837077 @default.
- W2801477219 cites W1987406340 @default.
- W2801477219 cites W1989195046 @default.
- W2801477219 cites W1992112921 @default.
- W2801477219 cites W1994193851 @default.
- W2801477219 cites W2013568031 @default.
- W2801477219 cites W2022286388 @default.
- W2801477219 cites W2023409962 @default.
- W2801477219 cites W2032760352 @default.
- W2801477219 cites W2049388096 @default.
- W2801477219 cites W2051332449 @default.
- W2801477219 cites W2060265857 @default.
- W2801477219 cites W2061215349 @default.
- W2801477219 cites W2062398476 @default.
- W2801477219 cites W2062495745 @default.
- W2801477219 cites W2065589690 @default.
- W2801477219 cites W2069124347 @default.
- W2801477219 cites W2073233871 @default.
- W2801477219 cites W2078446103 @default.
- W2801477219 cites W2079087277 @default.
- W2801477219 cites W2087377825 @default.
- W2801477219 cites W2139995033 @default.
- W2801477219 cites W2145756312 @default.
- W2801477219 cites W2158303916 @default.
- W2801477219 cites W2163382189 @default.
- W2801477219 cites W2310605948 @default.
- W2801477219 cites W2483488690 @default.
- W2801477219 cites W2563186034 @default.
- W2801477219 cites W2566996822 @default.
- W2801477219 cites W2583475973 @default.
- W2801477219 cites W2597228335 @default.
- W2801477219 cites W2604404809 @default.
- W2801477219 cites W2605249218 @default.
- W2801477219 cites W2621849512 @default.
- W2801477219 cites W2917837889 @default.
- W2801477219 cites W4210271223 @default.
- W2801477219 doi "https://doi.org/10.1016/j.msec.2018.05.011" @default.
- W2801477219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30033270" @default.
- W2801477219 hasPublicationYear "2018" @default.
- W2801477219 type Work @default.
- W2801477219 sameAs 2801477219 @default.
- W2801477219 citedByCount "40" @default.
- W2801477219 countsByYear W28014772192019 @default.
- W2801477219 countsByYear W28014772192020 @default.
- W2801477219 countsByYear W28014772192021 @default.
- W2801477219 countsByYear W28014772192022 @default.
- W2801477219 countsByYear W28014772192023 @default.
- W2801477219 crossrefType "journal-article" @default.
- W2801477219 hasAuthorship W2801477219A5009789022 @default.
- W2801477219 hasAuthorship W2801477219A5011690431 @default.
- W2801477219 hasAuthorship W2801477219A5014059510 @default.
- W2801477219 hasAuthorship W2801477219A5020397284 @default.
- W2801477219 hasAuthorship W2801477219A5025180804 @default.
- W2801477219 hasAuthorship W2801477219A5040353743 @default.
- W2801477219 hasAuthorship W2801477219A5054192701 @default.
- W2801477219 hasAuthorship W2801477219A5058106018 @default.
- W2801477219 hasAuthorship W2801477219A5058492742 @default.
- W2801477219 hasAuthorship W2801477219A5068506600 @default.
- W2801477219 hasAuthorship W2801477219A5077056772 @default.
- W2801477219 hasAuthorship W2801477219A5079609030 @default.
- W2801477219 hasAuthorship W2801477219A5085792068 @default.
- W2801477219 hasConcept C101335993 @default.
- W2801477219 hasConcept C109316439 @default.
- W2801477219 hasConcept C112613896 @default.
- W2801477219 hasConcept C121608353 @default.
- W2801477219 hasConcept C126322002 @default.
- W2801477219 hasConcept C150903083 @default.
- W2801477219 hasConcept C15920480 @default.
- W2801477219 hasConcept C159654299 @default.
- W2801477219 hasConcept C178790620 @default.
- W2801477219 hasConcept C185592680 @default.
- W2801477219 hasConcept C202751555 @default.
- W2801477219 hasConcept C203014093 @default.
- W2801477219 hasConcept C207001950 @default.
- W2801477219 hasConcept C2776231280 @default.
- W2801477219 hasConcept C2778019345 @default.
- W2801477219 hasConcept C2778695046 @default.
- W2801477219 hasConcept C2779820397 @default.
- W2801477219 hasConcept C2781230642 @default.